I-RegeneRx Biopharmaceuticals, Inc. inika ingxelo yokuba abaphandi baye babonisa ukuphumelela konyango lwe-Thymosin Beta 4 (Tβ4) njengonyango oludibeneyo oluchasene ne-hyperglycemia (isifo sikashukela) -utshintsho olwenziwe kwiiseli ze-corneal epithelial.
"Uphononongo lwethu lucacisa okokuqala ukuba i-Tβ4 kunye ne-vasoactive intestinal peptide (VIP) unyango lwe-combo ludlala indima ebalulekileyo ekulawuleni uzinzo oluqinileyo kunye ne-cytoskeleton rearrangement [ye-cornea], ehambelana ngokusondeleyo nesithintelo sengqibelelo. Ngaphaya koko, i-Tβ4 imisela ngamandla indima yayo njengonyango oluncedisayo kwizithintelo ze-corneal zesifo seswekile ezingenazo iziphumo ebezingalindelekanga, ngaloo ndlela zenza lula izinto ezingalunganga zeendlela ezikhoyo zokhathalelo [lweliso],” ngokweqela lophando.
Uphando luboniswe kwi-Association for Research in Vision and Ophthalmology (ARVO) 2022 intlanganiso, ebanjwe ngoMeyi 1-4, 2022, eDenver, eColorado. Iqela lophando libandakanya izazinzulu kunye noogqirha baseWayne State University School of Medicine eDetroit, MI; IYunivesithi yaseCentral Florida College of Health Professors kunye neSayensi e-Orlando, FL; kunye neYunivesithi yaseMansoura eMansoura, eYiputa. Uphando luxhaswe ngemali ngamaZiko ezeMpilo eSizwe, iZiko le-Eversight loMbono kunye noPhando lweBhanki yamehlo, kunye noPhando lokuNqanda ubumfama.
INTO ONOKUYITHATHA KWELI NQAKU:
- “Our study elucidates for the first time that a Tβ4 and vasoactive intestinal peptide (VIP) combo treatment plays a crucial role in regulating the tight junction stability and cytoskeleton rearrangement [of the cornea], which are closely related to barrier integrity.
- The research was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 meeting, held May 1-4, 2022, in Denver, Colorado.
- is reporting that researchers have demonstrated the therapeutic efficacy of Thymosin Beta 4 (Tβ4) as a combination treatment against hyperglycemia (diabetic)-induced changes in human corneal epithelial cells.
